London’s PolyModels Hub, a startup innovating the digital transformation of biopharma process development, has raised €7.9 million (£7 million) in a Series A round to expand its engineering and product teams, enhance its core platform, and reach more pharmaceutical organisations worldwide.
The round was led by Molten Ventures, with participation from Marathon Venture Capital.
“The pharmaceutical industry is undergoing a once-in-a-generation digital transformation. In just 18 months, our technology and exceptional team have delivered tangible value across multiple programmes, expanding these collaborations to a global scale,” says Antonio Benedetti, CEO & co-founder, PolyModels Hub.
PolyModels Hub’s raise is part of a broader trend in 2025, where digital and BioTech software solutions are increasingly attracting investment.
For instance, ScienceMachine, a London-based AI-driven BioTech data analysis startup, secured €2.9 million for product development. Similarly, Kiin Bio, also based in London, raised €1.9 million to launch a virtual scientist platform for drug discovery. Meanwhile, in Sweden, Cellcolabs raised €10.3 million to scale industrial‑scale stem-cell production, and EnsiliTech from the UK secured €5.2 million to reduce cold-chain costs in biopharma logistics.
Combined, these companies represent a total funding of around €20 million, further demonstrating growing interest in the intersection of digital innovation and the life sciences sector in Europe.
PolyModels Hub’s raise is especially significant as it highlights the increasing demand for scalable, data-driven infrastructure in biopharma R&D and manufacturing.
“We’re investing deeply in complex biologics and advancing our platform to empower scientists with the model-based solutions they deserve to transform molecules into medicines for the 21st century,” adds Benedetti.
Founded in 2023, PolyModels Hub is a BioTech software company developing the digital backbone for biopharma process development. Its flagship platform, ModelFlow, integrates data, models, and workflows to help scientists and engineers design, simulate, and optimise pharmaceutical processes faster and more reliably.
According to the company, developing a new drug typically costs around €2.8 billion ($2.5 billion), with roughly a quarter of that – about €738 million ($650 million) – spent on process development alone. Across the hundreds of therapies progressing through the pipeline each year, this represents a vast opportunity to make drug development faster, more efficient, and more reproducible.
Their platform, ModelFlow, brings together advanced modeling, simulation, and workflow management in one integrated digital environment. It allows scientists and engineers to design, test, and refine manufacturing processes faster, connecting data and expertise across teams and departments.
Ben Wilkinson, CEO, Molten Ventures, adds: “PolyModels Hub is solving a real pain point for pharma teams, bringing together deep domain expertise and cutting-edge technology in a way that’s genuinely transformative. We’re proud to support Antonio B, Antonio Y, Harry and the team as they scale their impact across the industry.
“What impressed us most is the team’s blend of technical know-how and deep understanding of their customers’ challenges. They’ve built a solution that delivers value in weeks, not years, and its rapid adoption across the industry speaks volumes.”
In conventional settings, scientists rely on dozens or even hundreds of laboratory experiments to optimise a single process – work that can take weeks or months to complete.
In early deployments, ModelFlow has reportedly reduced experimental workloads by more than 90%, turning 100-experiment workflows into fewer than ten while maintaining or improving scientific robustness.
These results speak to a broader shift underway across the industry. Pharmaceutical teams are recognizing that process development is not just a technical step, but a strategic lever for speed, quality, and regulatory success. As manufacturing becomes more complex – spanning small molecules, biologics, and emerging modalities – the need for scalable, data-driven infrastructure is only growing.
“Despite the technological and scientific progress, a large part of pharma still runs on archaic lab processes, delaying patients’ access to life-changing medicines. We are privileged to be day one partners with PolyModels Hub as they redefine how the industry designs, tests, and improves drug development processes using data and automation”, said Alex Alexakis, Partner, Marathon Venture Capital.
Read the orginal article: https://www.eu-startups.com/2025/11/with-e7-9-million-in-new-funding-polymodels-hubs-modelflow-reduces-biopharma-experimentation-by-90/
